drugset / Trial / NCT01244464
A Study of the Safety of IMOVAX Polio™ in China
Non-randomizedSingle-groupOpen-labelPrevention
Summary
This study is designed to obtain post-marketing safety data on IMOVAX Polio™ vaccine in China. Primary Objective: To describe the safety profile after each dose of IMOVAX Polio™ administered at 2, 3, and 4 months of age in population aged over 2 months old living in the study city China.
Timeline
- Start
- 2010-11
- Primary completion
- 2011-06
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Inactivated Polio Vaccine | Vaccine | 0.5 ml | Intramuscular |